Miromatrix Medical (NASDAQ:MIRO) and CareDx (NASDAQ:CDNA) entered an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs.
CareDx will develop an innovative testing solution for Miromatrix to use in pre-clinical animal models and will be the exclusive provider of donor-derived cell-free DNA testing services for use in human clinical studies to non-invasively assess acute allograft rejection in Miromatrix’s pipeline of human bioengineered organs.
“CareDx is at the leading edge of transplant innovation and has been instrumental in driving paradigm shifts in clinical practice through their non-invasive testing services which are widely used by leading organ transplant centers across the U.S.,” Jeff Ross Ph.D., CEO of Miromatrix, said in a statement.
“Our partnership with CareDx allows us to tap into their expertise in ways that may help us accelerate our momentum as we drive the next wave of innovation with bioengineered alternatives for use in human organ transplants,” he added.
It is estimated that more than 100,000 people in the U.S. are waiting for an organ transplant, but only slightly more than half of them are expected to receive an organ within five years. Some 17 people die each day waiting for an organ transplant.
